Swiss biopharmaceutical company ObsEva SA said it plans to list its stock on the SIX Swiss Exchange.
The company, which sold shares on the Nasdaq market last year, said it plans to list in Switzerland to raise its profile with European investors for future potential financing.
The listing will also help provide the company's shareholders with the protection offered by the Swiss takeover rules, ObsEva said in a statement.
The company also plans to maintain its listing on the Nasdaq Global Select Market.
ObsEva reported in February 2018 that its infertility treatment met the main goal of a late-stage study.
